GD2 CAR-T as consolidation in high-risk neuroblastoma
Give engineered GD2 T cells to children in remission after standard therapy, where the long-term data show the deepest and longest cures.
GD2-CART01 long-term follow-up: 5 of 8 patients infused with no evidence of disease remain disease-free at 10-15 years, versus ~50% relapse expected. Consolidation replaces or follows tandem transplant and anti-GD2 antibody.
Pages like this
not linked directly; found by shared links- PersonCrystal L. Mackall
Shares GD2-CART01 (Bambino Gesù phase 1/2), Armoured, logic-gated & next-gen CARs, GD2 (disialoganglioside), Neuroblastoma (paediatric).
- CompanyY-mAbs Therapeutics
Shares GD2 (disialoganglioside), Neuroblastoma (paediatric), Rare and paediatric cancers without markets.
- InstitutionTexas Children's Cancer and Hematology Center
Shares GD2 (disialoganglioside), Neuroblastoma (paediatric), Rare and paediatric cancers without markets, CAR-T cell therapy.
- TrialCOG ANBL0032
Shares GD2 (disialoganglioside), Neuroblastoma (paediatric), Rare and paediatric cancers without markets.
- PersonChristine E. Brown
Shares Armoured, logic-gated & next-gen CARs, CAR-T cell therapy.
- InstitutionDan L Duncan Comprehensive Cancer Center, Baylor College of Medicine
Shares GD2 (disialoganglioside), Neuroblastoma (paediatric), CAR-T cell therapy.
- ProductNaxitamab
Shares GD2 (disialoganglioside), Neuroblastoma (paediatric), Rare and paediatric cancers without markets.
- IdeaOne global paediatric cancer development plan instead of separate FDA and EMA plans
Shares Neuroblastoma (paediatric), Rare and paediatric cancers without markets.